MAP3K8 anticorps

N° du produit ABIN265369

Détail du produit anti-MAP3K8 anticorps

Antigène: MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MAP3K8 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)

Specificité: This antibody detects endogenous levels of MAP3K8 / TPL-2 protein(region surrounding Pro284).

Réactivité croisée (Details): Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human.

Purification: Affinity Chromatography using epitope-specific immunogen

Information d'application

Indications d'application: ELISA: 1/40000approx. 1/60000. Western Blot: 1/500approx. 1/1000. Immunofluorescence: 1/50approx. 1/200. Immunohistochemistry: 1/50approx. 1/200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH ~7.2, 0.05 % Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur MAP3K8

Antigène: MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))

Autre désignation: MAP3K8 / TPL-2 (MAP3K8 Produits)

Synonymes: anticorps MAP3K8, anticorps COT, anticorps EST, anticorps ESTF, anticorps MEKK8, anticorps TPL2, anticorps Tpl-2, anticorps c-COT, anticorps Cot, anticorps Cot/Tpl2, anticorps Est, anticorps Estf, anticorps Tpl2, anticorps D17TPL2, anticorps mitogen-activated protein kinase kinase kinase 8, anticorps MAP3K8, anticorps map3k8, anticorps Map3k8

Sujet: The role of mitogen-activated protein kinases (MAPKs) in cell signaling pathways is well established. The rat gene Tpl-2, for tumor progression locus 2, and the human and mouse homologues c-Cot, for cancer osaka thyroid oncogene, encode a proto-oncogene serine/threonine protein kinase that was shown to play a role in the functional activation of the MAP kinase pathway. Overexpression of Cot induces MAP kinase activation in COS-1 and NIH/3T3 cells. Cot-mediated activation of MAP kinase is inhibited by both Ras N17, a dominant negative mutant of c-H-Ras, and Raf-1s621A, a dominant negative mutant of Raf-1, suggesting that Cot functions upstream of Ras and Raf-1.Other studies have shown that a kinase-negative, dominant negative mutant of Cot partially blocks Ras or Raf-1-induced MAP kinase activation, arguing that Cot functions downstream of Ras and Raf-1. To explain these contrasting findings, it has been suggested that Cot, Ras and Raf-1 may form a multimeric complex that phosphorylates MEK-1. Cot has also been shown to be implicated in T lymphocyte activation.Synonyms: COT, COT proto-oncogene serine/threonine-protein kinase, Cancer Osaka thyroid oncogene, ESTF, MAPK, Mitogen-activated protein kinase kinase kinase 8, Tumor progression locus 2, Tumor progression locus 2

Poids moléculaire: approx. 53 kDa

ID gène: 1326

NCBI Accession: NP_005195

UniProt: P41279

Pathways: Signalisation PI3K-Akt, TCR Signaling